| Variable |
Presence of advanced fibrosis n=91 |
Absence of advanced fibrosis n=128 |
P value |
| Age (years) |
55 ± 11 |
50 ± 11 |
0.00 |
| Proportion Female (%) |
63 (69.2%) |
88 (68.8%) |
0.94 |
| BMI (kg/m2) |
36.3 ± 7.8 |
37.4 ± 8.05 |
0.32 |
| Presence of HTN (%) |
71 (78%) |
84 (65.6%) |
0.05 |
| Duration of DM (years) |
4.9 ± 6.3 |
4.6 ± 5.1 |
0.77 |
| Use of Insulin (%) |
26 (20.3%) |
26 (28.9%) |
0.14 |
| Use of Metformin (%) |
39 (42.9%) |
54 (42.2%) |
0.92 |
| Use of Sulfonylurea (%) |
35 (38.9%) |
32 (25.0%) |
0.03 |
| Use of Statin (%) |
31 (34.1%) |
56 (44.1%) |
0.14 |
| Use of Ace-I/ARB (%) |
41 (45.1%) |
65 (50.8%) |
0.40 |
| Serum Bilirubin (mg/dL) |
0.75 ± 0.49 |
0.65 ± 0.38 |
0.10 |
| AST (U/L) |
61.6 ± 37.6 |
48.9 ± 33.9 |
0.01 |
| ALT (U/L) |
65.2 ± 55.9 |
64.9 ± 45.7 |
0.96 |
| Albumin (g/dL) |
4.0 ± 0.6 |
4.2 ± 0.4 |
0.00 |
| INR |
1.06 ± 0.14 |
1.02 ± 0.20 |
0.10 |
| Platelet count (k/uL) |
202.0 ± 87.8 |
252.0 ± 65.2 |
0.00 |
| Creatinine (mg/dL) |
0.84 ± 0.29 |
0.87 ± 0.63 |
0.62 |
| Total cholesterol (mg/dL) |
178.8 ± 51.4 |
203.3 ± 55.3 |
0.00 |
| TG (mg/dL) |
204.6 ± 118.7 |
251.5 ± 279.5 |
0.18 |
| HDL (mg/dL) |
39.9 ± 11.5 |
42.6 ± 9.3 |
0.08 |
| LDL (mg/dL) |
108.0 ± 41.3 |
121.3 ± 47.1 |
0.06 |
| HbA1C (%) |
7.4 ± 1.4 |
7.3 ± 1.5 |
0.51 |
| Ferritin (ng/mL) |
213.3 ± 236.3 |
201.2 ± 234.2 |
0.74 |
| Grade of steatosis |
1.9± 0.9 |
1.9 ± 0.8 |
0.85 |
| Grade of lobular inflammation |
1.5 ± 0.6 |
1.5 ± 0.6 |
0.66 |
| Grade of ballooning |
1.5 ± 0.5 |
1.0 ± 0.7 |
0.00 |
| NAS |
5.0± 1.4 |
4.5 ± 1.7 |
0.02 |
Data expressed as mean ± SD or number and percentages (%).
SD: Standard Deviation; BMI: Body Mass Index; HTN: Hypertension; ACE-I:
Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin II Receptor
Blocker; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR:
International Normalised Ratio; TG: Triglyceride, HDL: High Density Lipoprotein
Cholesterol; LDL: Low Density Lipoprotein Cholesterol; NAS: NAFLD activity
score; NA: Not applicable. |
